These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15997385)

  • 61. Basic science for the clinician 46. Molecular biologic agents in development: possible clinical consequences to rheumatologists.
    Sigal LH
    J Clin Rheumatol; 2007 Oct; 13(5):286-90. PubMed ID: 17921801
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Role of the Institute of Rheumatology in formation and development of State controlling system of rheumatic diseases].
    Folomeeva OM; Amirdzhanova VN
    Vestn Ross Akad Med Nauk; 1998; (12):9-12. PubMed ID: 9987951
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Rheumatology--a glimpse of a rapidly developing discipline].
    Baslund B; Madsen OR; Søndergaard K; Juul L
    Ugeskr Laeger; 2012 Mar; 174(12):804. PubMed ID: 22433561
    [No Abstract]   [Full Text] [Related]  

  • 65. [Early stages of rheumatic diseases].
    Gross WL; Manns MP
    Internist (Berl); 2008 Mar; 49(3):261-2. PubMed ID: 18214407
    [No Abstract]   [Full Text] [Related]  

  • 66. [New biologics and orally available compounds. What is still in the pipeline?].
    Grünke M; Bastian H; Schulze-Koops H; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):626-32. PubMed ID: 20725732
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rheumatic Disease Clinics of North America. Drug safety: managing innovation in rheumatology. Foreword.
    Weisman MH
    Rheum Dis Clin North Am; 2012 Nov; 38(4):ix-x. PubMed ID: 23137584
    [No Abstract]   [Full Text] [Related]  

  • 68. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Total Joint Arthroplasty in Patients with Inflammatory Rheumatic Diseases.
    Compagnoni R; Gualtierotti R; Randelli P
    Adv Ther; 2018 Aug; 35(8):1133-1139. PubMed ID: 29995301
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Nocebo Effect in Rheumatology: An Unexplored Issue.
    Cantini F; Niccoli L; Franchi G; Damiani A; Benucci M
    Isr Med Assoc J; 2020 Mar; 22(3):185-190. PubMed ID: 32147985
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1175-87. PubMed ID: 21793791
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Seminars in research 2013: joint experiences using biologics in rheumatology and dermatology.
    Gisondi P; Murdaca G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S1-2. PubMed ID: 25381965
    [No Abstract]   [Full Text] [Related]  

  • 73. GISEA: an Italian biological agents registry in rheumatology.
    Lapadula G; Ferraccioli G; Ferri C; Punzi L; Trotta F;
    Reumatismo; 2011 Nov; 63(3):155-64. PubMed ID: 22257916
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potential bias in Kaplan-Meier survival analysis applied to rheumatology drug studies.
    Utley M; Gallivan S; Young A; Cox N; Davies P; Dixey J; Emery P; Gough A; James D; Prouse P; Williams P; Winfield J; Devlin JA
    Rheumatology (Oxford); 2000 Jan; 39(1):1-2. PubMed ID: 10662865
    [No Abstract]   [Full Text] [Related]  

  • 75. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
    Kristensen LE; Saxne T; Geborek P
    Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Continuous quick development of rheumatology].
    Madsen OR; Terslev L; Tarp U; Jacobsen S; Ostergaard M
    Ugeskr Laeger; 2009 Mar; 171(13):1092. PubMed ID: 19321087
    [No Abstract]   [Full Text] [Related]  

  • 77. [Personalized medicine in rheumatology - hype or hope?].
    Burmester GR; Feist E
    Z Rheumatol; 2013 Feb; 72(1):10-1. PubMed ID: 23392598
    [No Abstract]   [Full Text] [Related]  

  • 78. [What's new in infantile and adolescent rheumatology? Report of the 13th Anniversary of the Working Group on Infantile and Adolescent Rheumatology in Halle from 14 to 16 November 2003].
    Horneff G
    Z Rheumatol; 2005 Feb; 64(1):42-7. PubMed ID: 15756500
    [No Abstract]   [Full Text] [Related]  

  • 79. New Zealand rheumatology in 2004: realising the potential?
    Highton J
    N Z Med J; 2004 Apr; 117(1192):U842. PubMed ID: 15107866
    [No Abstract]   [Full Text] [Related]  

  • 80. [Dynamic developments in rheumatology].
    Müller-Ladner U; Rüther W
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1887. PubMed ID: 17823880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.